Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year price […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its price objective increased by TD Cowen from $59.00 to $61.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on RARE. Wedbush reissued a neutral rating […]
Royal Bank of Canada began coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $77.00 price target on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on RARE. JPMorgan Chase & Co. upped their […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.73) per share for the quarter. Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company […]
Ultragenyx Pharmaceutical (NASDAQ:RARE) Now Covered by Royal Bank of Canada themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.